Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Christopher Sweeney.
Connection Strength

3.939
  1. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019 09; 22(3):420-427.
    View in: PubMed
    Score: 0.205
  2. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
    View in: PubMed
    Score: 0.197
  3. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 07 02; 128(7):2979-2995.
    View in: PubMed
    Score: 0.196
  4. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):130-134.
    View in: PubMed
    Score: 0.191
  5. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018 03; 25(3):220-231.
    View in: PubMed
    Score: 0.190
  6. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
    View in: PubMed
    Score: 0.185
  7. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):726-734.
    View in: PubMed
    Score: 0.173
  8. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A. 2016 May 31; 113(22):6259-64.
    View in: PubMed
    Score: 0.170
  9. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. Clin Cancer Res. 2015 Dec 15; 21(24):5578-87.
    View in: PubMed
    Score: 0.162
  10. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
    View in: PubMed
    Score: 0.160
  11. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.
    View in: PubMed
    Score: 0.157
  12. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2015; 5(1):72-82.
    View in: PubMed
    Score: 0.154
  13. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7319-24.
    View in: PubMed
    Score: 0.148
  14. Elevated IL-8, TNF-a, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun; 74(8):820-8.
    View in: PubMed
    Score: 0.147
  15. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb; 74(3):225-34.
    View in: PubMed
    Score: 0.143
  16. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014 May 22; 33(21):2790-800.
    View in: PubMed
    Score: 0.139
  17. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
    View in: PubMed
    Score: 0.139
  18. Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. J Clin Oncol. 2013 Feb 20; 31(6_suppl):33.
    View in: PubMed
    Score: 0.136
  19. Use of elevated baseline IL-8, CCL-2, and TNFa to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). J Clin Oncol. 2012 Feb 10; 30(5_suppl):13.
    View in: PubMed
    Score: 0.127
  20. Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT). J Clin Oncol. 2012 Feb 10; 30(5_suppl):191.
    View in: PubMed
    Score: 0.127
  21. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
    View in: PubMed
    Score: 0.058
  22. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
    View in: PubMed
    Score: 0.057
  23. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547.
    View in: PubMed
    Score: 0.055
  24. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.054
  25. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532.
    View in: PubMed
    Score: 0.051
  26. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 09 20; 35(27):3097-3104.
    View in: PubMed
    Score: 0.046
  27. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211.
    View in: PubMed
    Score: 0.046
  28. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 06 01; 34(16):1913-20.
    View in: PubMed
    Score: 0.042
  29. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
    View in: PubMed
    Score: 0.041
  30. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Dec; 107(12):djv261.
    View in: PubMed
    Score: 0.041
  31. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.037
  32. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.037
  33. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond). 2013 May; 8(5):687-98.
    View in: PubMed
    Score: 0.033
  34. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.033
  35. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 04; 4(128):128ra39.
    View in: PubMed
    Score: 0.032
  36. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010 Dec 01; 304(21):2373-80.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.